Enliven Therapeutics, Inc. (ELVN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Enliven Therapeutics, Inc. (ELVN) closed at USD 39.28 on 2026-10-14, a change of +82.3 % over the past year, with a market capitalization of USD 2.88B.

Enliven Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Enliven Therapeutics, Inc. key figures

Previous close

USD 39.28 (2026-10-14)

1-year change

+82.3 %

Market cap

USD 2.88B

Enterprise value

USD 1.99B

P/E ratio (trailing)

-23.69

P/E ratio (forward)

-16.71

EPS (trailing)

-1.66

EPS (forward)

-2.35

PEG ratio

n/a

Price to book

3.22

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.20

Employees

67

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Enliven Therapeutics, Inc. and compare it with other stocks.